If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
  Australasian PsychiatryVolume 10 Issue 1, Pages 54 - 58 Published Online: 26 Feb 2002 2006 Royal Australian and New Zealand College of Psychiatrists
Abstract | References | Full Text: HTML, PDF (Size: 174K) | Related Articles | Citation Tracking  The development of Clinical Guidelines for the use of Zuclopenthixol Acetate Copyright Royal Australian and New Zealand College of Psychiatrists KEYWORDS clinical guidelines • zuclopenthixol acetate ABSTRACTObjective: This paper illustrates the process that was undertaken in the development of guidelines for the use of Zuclopenthixol Acetate (ZA) and presents the guidelines that were developed at the end of this process. Conclusions: A number of investigations were undertaken to inform the above process, including: (i) A questionnaire sent to College Fellows and psychiatric registrars, to assess their use of ZA in the management of acute arousal in psychosis. This highlighted the lack of confidence that clinicians had in using ZA and some deficits in knowledge that confirmed the local need for such guidelines; (ii) A retrospective audit of the use of ZA in two psychiatric intensive care units over a 6 month period. This revealed significant differences between the centres in the manner in which ZA was prescribed; (iii) A review of published studies on ZA. |  |
